Pan-fungal screening is also called the BDG test, which stands for (1, 3)-β-D-glucan test. Many fungi, such as Candida, Fusarium, and Aspergillus, contain (1-3)-β-D-glucan in their cell wall polysaccharides, while bacteria, viruses, and human cells do not have this component.
The BDG test detects (1-3)-β-D-glucan in the fungal cell wall and is used for the early diagnosis of deep fungal infections, especially Candida and Aspergillus infections. It cannot be used for the diagnosis of cryptococcal and zygomycete infections (Mucor, Rhizopus, etc.).
Although it cannot distinguish the types of infected fungi, its negative results are of great significance in excluding invasive fungal diseases.
Dynamiker provides above 3 methods: dynamic colorimetric assay, ELISA assay and immunofluorescent assay to meet the detection needs of different medical scenarios.
Dynamiker pioneered the "5G+ Panel Testing" in Fungal Disease Serology, which can make up for the limitations of a single test item through the combined detection of multiple in vitro diagnostic reagents, and can combine the advantages of each test item to improve the clinical compliance rate, help doctors accurately judge the condition, guide medication, and thus improve the cure rate of patients and achieve accurate diagnosis and treatment.